These nanoparticles, known as Topas Particle Conjugates (TPCs), carry disease-related peptide epitopes and are engineered for targeted delivery into the liver sinusoidal endothelial cells (LSECs). A key advantage is that our TPCs offer a versatile mechanism to conjugate and combine immunogenic peptides of choice. This targeted approach induces antigen-specific tolerance, ensuring rapid clearance from circulation and preventing undesired systemic and immune reactions.

Tolerance induction by the LSECs is designed to produce a robust, long-lasting natural immunomodulation through the induction of regulatory T cells (Tregs). Tregs are crucial for maintaining immune tolerance, thereby reducing the likelihood of adverse immune responses. A stable population of Tregs equips the body to manage immune challenges more effectively, leading to fewer inflammatory episodes and improved overall health.